October 29, 2026 Brixton Biosciences Announces Pivotal Clinical Data for Reneurx™ Nerve-Selective Therapy in Knee Osteoarthritis to be Presented at AAHKS 2026 Read More Read the Article
October 26, 2026 Brixton Biosciences Strengthens Executive Leadership Team to Support the Next Phase of Company Growth Read More Read the Article
August 18, 2026 Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis Read More Read the Article
October 21, 2025 Brixton Biosciences Announces Scientific Advisory Board Leadership Read More Read the Article
October 24, 2024 Brixton Biosciences Receives $2M NIH HEAL Initiative Grant to Drive Drug-Free Pain Relief Innovations Read More Read the Article
May 14, 2024 Brixton Biosciences Announces $35M in Series B Funding to Advance Novel Technology for the Treatment of Pain Read More Read the Article
Loading page
Loading page
